(Total Views: 394)
Posted On: 02/01/2022 5:29:33 PM
Post# of 1418
Since this deal is now imminent, a reminder of a key point
The plan is for 3CL Sciences to be a majority owned subsidiary of Todos. The plan is for 3CL Sciences to raise funds directly by the sub.
Exactly how do you short, play games or manipulate a sub's share price when that happens?
You can't. The money 3CL Sciences raises won't be based on the share price of Todos today, tomorrow or next week.
Game over
If fact, sales of Tollovid could fund a good portion independently. You don't try to buy your own manufacturing facilities unless your sales projections are very high.
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma - November 29, 2021 9:08am EST
"As a majority owned subsidiary, 3CL Sciences will separate our critical scientific development work in COVID-19 from our other important development-stage work in cancer & Alzheimer’s diagnostics, as well as our revenue generating PCR & cPass neutralizing antibody testing services that we offer via our Provista Diagnostics CLIA/CAP lab in the United States. This structure gives us the most flexibility to attract traditional direct private investment into 3CL Sciences from major private institutional investors with the potential to maximize its future value independently to the benefit of Todos shareholders, while limiting ordinary share dilution.” "
https://investor.todosmedical.com/news-events...cquire-all
The plan is for 3CL Sciences to be a majority owned subsidiary of Todos. The plan is for 3CL Sciences to raise funds directly by the sub.
Exactly how do you short, play games or manipulate a sub's share price when that happens?
You can't. The money 3CL Sciences raises won't be based on the share price of Todos today, tomorrow or next week.
Game over
If fact, sales of Tollovid could fund a good portion independently. You don't try to buy your own manufacturing facilities unless your sales projections are very high.
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma - November 29, 2021 9:08am EST
"As a majority owned subsidiary, 3CL Sciences will separate our critical scientific development work in COVID-19 from our other important development-stage work in cancer & Alzheimer’s diagnostics, as well as our revenue generating PCR & cPass neutralizing antibody testing services that we offer via our Provista Diagnostics CLIA/CAP lab in the United States. This structure gives us the most flexibility to attract traditional direct private investment into 3CL Sciences from major private institutional investors with the potential to maximize its future value independently to the benefit of Todos shareholders, while limiting ordinary share dilution.” "
https://investor.todosmedical.com/news-events...cquire-all
(1)
(0)
